<DOC>
	<DOCNO>NCT00853710</DOCNO>
	<brief_summary>The aim study compare diagnostic performance simple rapid PSA assay whole blood standard plasma PSA assay .</brief_summary>
	<brief_title>Test Semiquantitative Prostate Specific Antigen ( PSA )</brief_title>
	<detailed_description>Screening surveillance prostate cancer typically involve sensitive laboratory technique quantification plasma prostate specific antigen ( PSA ) . In study , determine sensitivity specificity simple test strip base PSA assay use drop whole blood compare standard plasma PSA assay . Blood sample take hundred patient follow prostatic disease need PSA surveillance . Before decantation sample , drop blood serve rapid test strip . Plasma PSA level determine TRACE ( `` Time Resolved Amplified Cryptate Emission '' ) technology homogeneous liquid phase . The result rapid test compare plasma level obtain TRACE .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Diseases</mesh_term>
	<criteria>Patients follow prostate cancer symptomatic benign prostatic disease , PSA assay indicate . Patients must give informed consent . Patients follow disease prostatic .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Prostate-Specific Antigen</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Cancer</keyword>
	<keyword>Assay</keyword>
</DOC>